Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 44-46

  Epenetos, A A ^a,b   Hird, V ^b   Lambert, H ^c   Mason, P ^b   Coulter, C ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM; YTTRIUM 90;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SURVIVAL TIME;

EID: 0034004410     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99510.x     Document Type: Article

References (17)

1. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A gynecologic oncology group study. J Clin Oncol 1998; 16: 2620-2624.
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian center. N Engl J Med 1996; 335: 1950-5.
3. Miller BA, Ries LAG, Hankey BF et al, eds. SEER cancer statistics review: 1973-1990. Bethesda, MD: National Cancer Institute, 1993 (NIH publication no. 93-2789).
4. McGuire WP, Hoskins WJH, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
5. Ehrlich P. Collected studies on immunity. Translated by C. Bolduan. New York: John Wiley and Sons, 1906, p. 441.
6. Epenetos AA, Britton KE, Mather S et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours. Lancet 1982; ii: 999-1005.
7. Epenetos AA, Kosmas C. Monoclonal antibodies for imaging and therapy. Br J Cancer 1989; 59: 152-5.
8. Epenetos AA, Snook D, Durbin H et al. Limitations of radiolabelled monoclonal antibodies for the localisation of human neoplasms. Cancer Res 1986; 46: 3183-91.
9. Epenetos AA, Courtenay-Luck N, Halnan KE et al. Antibody guided irradiation of malignant lesions: three case studies illustrating a new method of treatment. Lancet 1984; i: 1441-3.
10. Epenetos AA, Munro AJ, Stewart S et al. Antibody guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabelled monoclonal antibodies. J Clin Oncol 1987; 5: 1890-9.
11. Gupta RK, Hird V, Slevin ML et al. Treatment of ascites and pleural effusions due to malignant disease using iodine-131-labelled tumor-associated monoclonal antibodies. Tumor Targeting 1996; 2: 1351-8.
12. Hird V, Maraveyas A, Snook D et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-6.
13. Nicholson S, Gooden CSR, Hird V et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis. Oncology Reports 1998; 5: 223-6.
14. Maraveyas A, Snook D, Hird V et al. Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994; 73: 1067-75.
15. Stewart JSW, Hird V, Snook D et al. Intraperitoneal Yttrium-90-labelled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941-50.
16. Pecorelli S, et al. Carcinoma of the ovary. FIGO Annual Report 1998. J Epidemiol Biostat 1998; 1: 75-102.
17. Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL et al. Long-term survival in ovarian cancer. Matured data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.